SEC Tracker
Get the app

Black Diamond Therapeutics BDTX

Black Diamond Therapeutics reports positive Phase 2 results for silevertinib

Black Diamond Therapeutics (BDTX) filed an 8-K with the SEC on Nov 10, 2026, 6:29 am ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. 86% CNS-ORR in patients with untreated brain metastases
  2. mPFS double that of current EGFR TKIs
  3. Cash and investments of $102.0 million as of September 30, 2026
  4. FDA supports potential accelerated approval based on CNS-ORR

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Black Diamond Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.